Cogent Biosciences, Inc.

XNASHealth care

Last traded price · USD

$31.70

+0.67%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 16:00 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $31.49
Volume: 28
Day's high: —
Day's low: —

In brief

Cogent Biosciences, Inc. is a health care company listed on Nasdaq, valued at about $5.50B.
Its shares closed at $31.49 on 4 Nov 2026, up 122.9% over the past year.
From India you can buy COGT in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Cogent Biosciences, Inc. (COGT) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole COGT share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade COGT options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: +3.7% (SPY −1.6%, XLV +13.5%). 3 months: −25.5% (SPY −0.4%, XLV +15.5%). 1 year: +122.9% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: COGT, SPY and XLV · as of 4 Nov 2026
8.9 days to cover short interest
19.7M shares were sold short at the 15 Oct 2026 settlement, 11.3% of the 173.5M shares outstanding; covering them would take 8.9 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $31.49 was 1.8% below its 50-day average ($32.08) and 11.5% below its 200-day average ($35.58). It has closed below the 200-day for 48 sessions, since 28 Aug 2026. The 50-day average crossed below the 200-day on 30 Sep 2026, 25 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
59% of the way up its 52-week range
Closed at $31.49 on 4 Nov 2026: 28.0% below the 52-week high of $43.73 (8 Dec 2025) and 126.0% above the low of $13.93 (7 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+3.7%

6 months−12.2%

1 year+122.9%

5 years+264.0%

Newswire

About

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

Website

Notable moves

November 10, 2025
+119.03%
February 14, 2024
+59.34%
June 10, 2022
+58.67%

Newswire

About

Website

Notable moves

November 10, 2025
+119.03%
February 14, 2024
+59.34%
June 10, 2022
+58.67%

Cogent Biosciences, Inc.

XNASHealth care

Last traded price · USD

$31.70

+0.67%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 16:00 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $31.49
Volume: 28
Day's high: —
Day's low: —

In brief

Cogent Biosciences, Inc. is a health care company listed on Nasdaq, valued at about $5.50B.
Its shares closed at $31.49 on 4 Nov 2026, up 122.9% over the past year.
From India you can buy COGT in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Cogent Biosciences, Inc. (COGT) shares from India?

Do I need the price of a whole COGT share to invest?

How much can I invest in US stocks in a year?

Can I trade COGT options or futures?

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: +3.7% (SPY −1.6%, XLV +13.5%). 3 months: −25.5% (SPY −0.4%, XLV +15.5%). 1 year: +122.9% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: COGT, SPY and XLV · as of 4 Nov 2026
8.9 days to cover short interest
19.7M shares were sold short at the 15 Oct 2026 settlement, 11.3% of the 173.5M shares outstanding; covering them would take 8.9 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $31.49 was 1.8% below its 50-day average ($32.08) and 11.5% below its 200-day average ($35.58). It has closed below the 200-day for 48 sessions, since 28 Aug 2026. The 50-day average crossed below the 200-day on 30 Sep 2026, 25 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
59% of the way up its 52-week range
Closed at $31.49 on 4 Nov 2026: 28.0% below the 52-week high of $43.73 (8 Dec 2025) and 126.0% above the low of $13.93 (7 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+3.7%

6 months−12.2%

1 year+122.9%

5 years+264.0%

Newswire

About

Website

Notable moves

November 10, 2025
+119.03%
February 14, 2024
+59.34%
June 10, 2022
+58.67%

Newswire

About

Website

Notable moves

November 10, 2025
+119.03%
February 14, 2024
+59.34%
June 10, 2022
+58.67%

Cogent Biosciences, Inc.

Cogent Biosciences, Inc. in brief

Ahead of SPY and its sector fund XLV over 1 year

8.9 days to cover short interest

Below its 50- and 200-day averages

59% of the way up its 52-week range

Cogent Biosciences, Inc.

Cogent Biosciences, Inc. in brief

Ahead of SPY and its sector fund XLV over 1 year

8.9 days to cover short interest

Below its 50- and 200-day averages

59% of the way up its 52-week range